Table 2.
Baseline and Time-Updated FGF-23 and Risks for the KRT Outcome and the Composite Outcome of KRT or Death
| KRT (n = 728 events) | KRT or Death (n =859 events) | |||
|---|---|---|---|---|
| Weighted Cox Models | Baseline FGF-23a | Time-Updated FGF-23b | Baseline FGF-23a | Time-Updated FGF-23b |
| Unadjusted HR | 1.79 (1.64–1.96) | 2.21 (2.01–2.42) | 1.78 (1.63–1.94) | 2.13 (1.95–2.33) |
| Model 1 HR | 1.81 (1.62–2.03) | 2.29 (2.07–2.53) | 1.81 (1.62–2.02) | 2.18 (1.98–2.40) |
| Model 2 HR | 1.22 (1.07–1.40) | 1.54 (1.39–1.70) | 1.27 (1.12–1.43) | 1.52 (1.38–1.67) |
| Model 3 HR | 1.19 (1.04–1.37) | 1.57 (1.41–1.74) | 1.23 (1.09–1.39) | 1.54 (1.40–1.69) |
| Model 4 HR | 1.18 (1.02–1.37) | 1.66 (1.49–1.86) | 1.21 (1.06–1.38) | 1.62 (1.47–1.78) |
| Time-varying IPW discrete time failure models, fully adjustedb | Not estimated | 1.94 (1.51–2.49) | Not estimated | 2.12 (1.64–2.73) |
Note: All results are reported per 1-SD increase in natural log-transformed FGF-23 level with SD representing the ln(FGF-23) distribution at the CRIC Study baseline visit. Median duration of subsequent follow-up was 6.3 years in 1,597 total participants at risk. Model 1, stratified by center and adjusted for age, sex, race, and ethnicity. Model 2, model 1 plus estimated glomerular filtration rate, urine protein-creatinine ratio, serum albumin, hemoglobin, CRP (baseline), and IL-6 (baseline) values. Model 3, model 2 plus diabetes, smoking, systolic blood pressure, body mass index, history of coronary artery disease, history of heart failure, history of stroke, history of peripheral vascular disease, number of hypertension medications, and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use. Model 4: model 3 plus calcium, phosphate, and parathyroid hormone levels.
Abbreviations: CRIC, Chronic Renal Insufficiency Cohort; CRP, C-reactive protein; FGF-23, fibroblast growth factor 23; HR, hazard ratio; IL-6, interleukin 6; IPW, inverse probability weighting; KRT, kidney replacement therapy; SD, standard deviation.
Adjusted for covariates at the baseline visit.
Adjusted for time-updated covariates, except sex, race, ethnicity, and CRP and IL-6 levels.